Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Influenza Vaccine Effectiveness in the United States during the 2016-2017 Season.

Flannery B, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Rolfes MA, Spencer S, Fry AM; US Flu VE Investigators.

Clin Infect Dis. 2018 Sep 11. doi: 10.1093/cid/ciy775. [Epub ahead of print]

PMID:
30204854
2.

2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type.

Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, Monto AS, McLean HQ, Belongia EA, Gaglani M, Murthy K, Fry AM, Flannery B; US Flu VE Investigators; U.S. Flu VE Investigators.

Clin Infect Dis. 2016 Dec 15;63(12):1564-1573. Epub 2016 Oct 4.

3.

Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014-2015 season.

McLean HQ, Caspard H, Griffin MR, Poehling KA, Gaglani M, Belongia EA, Talbot HK, Peters TR, Murthy K, Ambrose CS.

Vaccine. 2017 May 9;35(20):2685-2693. doi: 10.1016/j.vaccine.2017.03.085. Epub 2017 Apr 10.

4.

Moderate influenza vaccine effectiveness against influenza A(H1N1)pdm09 virus and low effectiveness against A(H3N2) virus among older adults during 2013-2014 influenza season in Beijing, China.

Zhang L, Pan Y, Ma C, Duan W, Sun Y, Wu S, Zhang M, Tian Y, Zheng Y, Yang P, Wang Q.

Hum Vaccin Immunother. 2018 Jun 3;14(6):1323-1330. doi: 10.1080/21645515.2018.1441655. Epub 2018 Apr 11.

PMID:
29461909
5.

Influenza vaccine effectiveness in older adults compared with younger adults over five seasons.

Russell K, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Flannery B.

Vaccine. 2018 Feb 28;36(10):1272-1278. doi: 10.1016/j.vaccine.2018.01.045.

PMID:
29402578
6.

Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses.

Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, Fonseca K, Winter AL, Gubbay JB, Krajden M, Petric M, Charest H, Bastien N, Kwindt TL, Mahmud SM, Van Caeseele P, Li Y.

PLoS One. 2014 Mar 25;9(3):e92153. doi: 10.1371/journal.pone.0092153. eCollection 2014.

7.

Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay J, Fonseca K, Charest H, Krajden M, Petric M, Mahmud SM, Van Caeseele P, Bastien N, Eshaghi A, Li Y.

J Infect Dis. 2015 Sep 1;212(5):726-39. doi: 10.1093/infdis/jiv177. Epub 2015 Mar 17.

PMID:
25784728
8.
9.

The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).

Valenciano M, Kissling E, Reuss A, Jiménez-Jorge S, Horváth JK, Donnell JM, Pitigoi D, Machado A, Pozo F; I-MOVE Multicentre Case Control Study Team.

Vaccine. 2015 Jun 4;33(24):2813-22. doi: 10.1016/j.vaccine.2015.04.012. Epub 2015 Apr 28.

10.

Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.

Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horváth JK, Domegan L, Pitigoi D, Machado A, Paradowska-Stankiewicz IA, Bella A, Larrauri A, Ferenczi A; Joan O´Donell, Lazar M, Pechirra P, Korczyńska MR, Pozo F, Moren A; I-MOVE multicentre case-control team.

Euro Surveill. 2016;21(7):pii=30139. doi: 10.2807/1560-7917.ES.2016.21.7.30139. Erratum in: Euro Surveill. 2016;21(8). doi: 10.2807/1560-7917.ES.2016.21.8.30145.

11.

Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015.

Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Petrie JG, McLean HQ, Belongia EA, Gaglani M, Berman L, Foust A, Sessions W, Thaker SN, Spencer S, Fry AM; Centers for Disease Control and Prevention.

MMWR Morb Mortal Wkly Rep. 2015 Jan 16;64(1):10-5.

12.

Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada.

Andrew MK, Shinde V, Hatchette T, Ambrose A, Boivin G, Bowie W, Chit A, Dos Santos G, ElSherif M, Green K, Haguinet F, Halperin SA, Ibarguchi B, Johnstone J, Katz K, Langley JM, LeBlanc J, Loeb M, MacKinnon-Cameron D, McCarthy A, McElhaney J, McGeer A, Nichols MK, Powis J, Richardson D, Semret M, Stiver G, Trottier S, Valiquette L, Webster D, Ye L, McNeil SA; Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Serious Outcomes Surveillance Network and the Toronto Invasive Bacterial Diseases Network (TIBDN).

BMC Infect Dis. 2017 Dec 29;17(1):805. doi: 10.1186/s12879-017-2905-8.

13.

Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.

Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, Gubbay JB, Dickinson JA, Fonseca K, Charest H, Bastien N, Li Y, Kwindt TL, Mahmud SM, Van Caeseele P, Krajden M, Petric M.

J Infect Dis. 2014 Jul 1;210(1):126-37. Epub 2014 Jan 19.

PMID:
24446529
14.

Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13.

Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen JM, Nunes B, Rogalska J, Pitigoi D, Paradowska-Stankiewicz I, Reuss A, Jiménez-Jorge S, Daviaud I, Guiomar R, O'Donnell J, Necula G, Głuchowska M, Moren A.

Euro Surveill. 2014 Feb 13;19(6). pii: 20701.

15.

Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season.

Puig-Barberà J, Guglieri-López B, Tortajada-Girbés M, López-Labrador FX, Carballido-Fernández M, Mollar-Maseres J, Schwarz-Chavarri G, Baselga-Moreno V, Mira-Iglesias A, Díez-Domingo J; Valencia Hospital Network for the Study of Influenza, Respiratory Viruses Disease.

Vaccine. 2017 Dec 19;35(52):7331-7338. doi: 10.1016/j.vaccine.2017.10.100. Epub 2017 Nov 8.

16.

Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results.

Pebody R, Warburton F, Andrews N, Ellis J, von Wissmann B, Robertson C, Yonova I, Cottrell S, Gallagher N, Green H, Thompson C, Galiano M, Marques D, Gunson R, Reynolds A, Moore C, Mullett D, Pathirannehelage S, Donati M, Johnston J, de Lusignan S, McMenamin J, Zambon M.

Euro Surveill. 2015;20(36). doi: 10.2807/1560-7917.ES.2015.20.36.30013.

17.

Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus.

Martínez-Baz I, Navascués A, Pozo F, Chamorro J, Albeniz E, Casado I, Reina G, Cenoz MG, Ezpeleta C, Castilla J; Primary Health Care Sentinel Network and Network for Influenza Surveillance in Hospitals of Navarra.

Hum Vaccin Immunother. 2015;11(7):1626-33. doi: 10.1080/21645515.2015.1038002.

18.

Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay JB, Drews SJ, Martineau C, Charest H, Krajden M, Bastien N, Li Y.

J Infect Dis. 2017 Dec 19;216(12):1487-1500. doi: 10.1093/infdis/jix526.

19.

Effectiveness of influenza vaccine in preventing medically-attended influenza virus infection in primary care, Israel, influenza seasons 2014/15 and 2015/16.

Yaron-Yakoby H, Sefty H, Pando R, Dichtiar R, Katz MA, Stein Y, Mandelboim M, Mendelson E, Shohat T, Glatman-Freedman A; The Israeli Influenza Surveillance Network (IISN).

Euro Surveill. 2018 Feb;23(7). doi: 10.2807/1560-7917.ES.2018.23.7.17-00026.

20.

Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015.

Flannery B, Zimmerman RK, Gubareva LV, Garten RJ, Chung JR, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Ohmit SE, Belongia EA, McLean HQ, Gaglani M, Piedra PA, Mishin VP, Chesnokov AP, Spencer S, Thaker SN, Barnes JR, Foust A, Sessions W, Xu X, Katz J, Fry AM.

J Infect Dis. 2016 Oct 1;214(7):1010-9. doi: 10.1093/infdis/jiw181. Epub 2016 May 6.

Supplemental Content

Support Center